Literature DB >> 27775276

[Enterocolitis associated with Hirschsprung's Disease. Experience in a pediatric teaching hospital].

S Castañeda Espinosa1, A García Giraldo1, P Jaimes de la Hoz1, L Jaramillo Barberi2, M A Perilla López1, M Méndez Manchola1, J A Niño Salcedo1, F Fierro Ávila1.   

Abstract

Hirschsprung's associated enterocolitis (HAEC) is the most serious and potentially fatal complication of the disease, with a significant morbidity and mortality. The effect of HAEC varies remarkably among the publications since the lack of consensus and the absence of established diagnostic criteria. Patients diagnosed with Hirschsprung's disease (HD) were selected and treated between January 2009 and December 2012 in Fundación HOMI, finding 41 cases of HD, 6 of them with total aganglionosis. 76% of the patients had HAEC, 18 of them during the neonatal period and 6 of them after the final pull-through; 23% presented recurrent enterocolitis episodes. HAEC was the first clinical manifestation in 25 (61%) of the patients with HD. From HD patients limited to the rectum and sigmoid 67% had enterocolitis unlike TCA (total colonic agangliniosis) cases in which all presented HAEC episodes. In our setting, HAEC remains to be an unknown complication; this revision demonstrates its high incidence and mortality.

Entities:  

Keywords:  Enterocolitis; Hirschsprung’s disease; Hirschsprung’s disease reintervention

Year:  2014        PMID: 27775276

Source DB:  PubMed          Journal:  Cir Pediatr        ISSN: 0214-1221


  2 in total

1.  Feasibility and efficacy of home rectal irrigation in neonates and early infancy with Hirschsprung disease.

Authors:  Changgui Lu; Hua Xie; Hongxing Li; Qiming Geng; Huan Chen; Xuming Mo; Weibing Tang
Journal:  Pediatr Surg Int       Date:  2019-09-18       Impact factor: 1.827

2.  Clinical predictors of readmission after surgery for Hirschsprung disease.

Authors:  Jie Min; Peng Cai; Bin Wu; Zhicheng Gu; Shungen Huang; Jian Wang
Journal:  Medicine (Baltimore)       Date:  2021-03-19       Impact factor: 1.817

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.